DHR stock forecast, quote, news & analysis

Key Takeaways

• Danaher shares closed at $211.81 on September 18, 2026, roughly 3% below their late-August level near $218.85, as investors digested a revised growth outlook.
• Second-quarter revenue rose 5.5% year over year to $6.3 billion, while adjusted diluted EPS of $1.94 beat consensus estimates and grew about 8%.
• Management narrowed full-year core revenue growth guidance to 3%–4% while raising its adjusted EPS forecast to $8.45–$8.60.
• Bioprocessing orders grew by a mid-teens percentage, but more than $100 million in shipments shifted into next year, pressuring near-term biotechnology revenue.
• Wall Street remains broadly constructive, with a consensus Buy rating and an average analyst price target near $229.

Current Market Snapshot

Danaher Corporation trades around $211, a level that leaves the stock below its earlier-2026 high near $243. The shares pulled back sharply following the July 21, 2026 earnings report, when a trimmed revenue outlook overshadowed an otherwise better-than-expected quarter, before recovering through September. Over the trailing month, the stock has been roughly flat to modestly lower, reflecting a market still weighing a recovering life sciences cycle against near-term shipment-timing headwinds in biotechnology. Broader sector sentiment has improved as biotech and pharmaceutical customers increase research and manufacturing spending after a prolonged post-pandemic slowdown, though investors remain focused on the pace of the bioprocessing recovery.

Danaher (DHR) Business Overview and Competitive Position

Danaher is a global science and technology company that designs, manufactures, and markets professional, medical, research, and industrial products. Its portfolio is organized around three segments: Diagnostics, Life Sciences, and Biotechnology. Major businesses include Beckman Coulter, Cepheid, Leica Biosystems, Radiometer, Cytiva, Pall, SCIEX, Integrated DNA Technologies, Aldevron, and Abcam. Following the 2023 separation of its environmental and applied solutions business into Veralto (VLTO), Danaher has focused squarely on life sciences and diagnostics. The company's operating model, the Danaher Business System, emphasizes continuous improvement, productivity, and disciplined capital deployment, and is a core reason investors follow the stock through market cycles.

Recent Developments Driving DHR

Danaher's July earnings report set the tone for recent trading. The company beat on both revenue and profit, delivered its strongest Life Sciences quarter in several years, and raised full-year adjusted EPS guidance to $8.45–$8.60 from $8.35–$8.55. However, management narrowed full-year core revenue growth to 3%–4% from 3%–6% and guided third-quarter core growth of just 2%–3%, citing a roughly 250 basis-point headwind from respiratory testing and a timing shift of more than $100 million in bioprocessing shipments into next year. The stock fell sharply before recovering as analysts turned more constructive.

Analyst actions have been supportive: UBS initiated coverage with a Buy rating and a $250 price target in early September, while Goldman Sachs (GS) raised its target to $250 from $210, HSBC to $250 from $230, and Baird to $238 from $232 with an Outperform rating. Corporate developments include the earlier-than-anticipated June completion of the Masimo acquisition, the announced acquisition of StatLab by Leica Biosystems, a regular quarterly dividend of $0.40 per share, and a confirmed leadership transition with Julie Sawyer Montgomery set to become President and CEO on October 1, 2026. A competitor's biopsy-needle recall also created a modest share-gain opportunity for Danaher's Mammotome business.

Trending AI Robots

Investors tracking Danaher alongside the broader market may also find value in automated trading tools. Tickeron's Trending AI Robots page highlights a curated selection of the platform's top-performing and most relevant AI trading bots. Tickeron offers hundreds of AI bots that collectively trade thousands of tickers, but only those demonstrating strong performance and relevance appear in this featured section. The bots vary widely in strategy, timeframe, and performance metrics, giving users a view into different approaches to automated trading. Exploring the section can help traders identify active strategies and decide whether algorithmic tools fit their own research process.

2026 Outlook and What Investors Should Watch

Danaher's forward trajectory hinges on several factors. The most closely watched is bioprocessing demand, where mid-teens order growth suggests underlying strength even as shipment timing weighs on reported revenue. Investors will monitor whether that deferred revenue materializes in 2027 and whether the business can exit 2026 at the mid-single-digit core growth rate management has signaled. Respiratory testing remains a year-over-year headwind through the second half, while China and other high-growth markets, where core revenue grew more than 10% in the quarter, are a key swing factor. The integration of Masimo and the pending StatLab acquisition will also shape the diagnostics franchise, as will the transition to incoming CEO Julie Sawyer Montgomery. Continued strength in Life Sciences, margin execution, and capital deployment through buybacks and M&A are additional catalysts to watch. These factors are forward-looking, and actual results may differ from current expectations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations